CUP Syndrome-Metastatic Malignancy with Unknown Primary Tumor

Area of Science:

• Oncology
• Diagnostic Imaging
• Molecular Pathology

Background:

• Cancer of unknown primary (CUP) represents 2-4% of newly diagnosed malignant diseases.
• CUP is a significant entity, ranking among the top 6 most common cancers in Germany.
• Advances in diagnostics and treatment strategies are improving outcomes for CUP patients.

Purpose of the Study:

• To review current diagnostic and therapeutic strategies for cancer of unknown primary.
• To highlight the role of advanced imaging and molecular diagnostics in CUP management.
• To discuss treatment approaches for both localized and disseminated CUP.

Main Methods:

• Selective PubMed search focusing on recent publications (past decade).
• Inclusion of current guidelines and recommendations from specialty societies.
• Evaluation of diagnostic modalities including imaging, immunohistochemistry, and molecular-genetic testing.

Main Results:

• Up to 40% of CUP cases have their primary tumor identified through advanced diagnostics.
• Common primary tumor origins include lung, pancreas, liver, and biliary system.
• Treatment varies from surgical resection/radiotherapy for local disease to systemic therapy for disseminated CUP, with a median 2-year survival of 20% for the latter.
• Immunomodulatory antibodies show potential but are currently experimental.

Conclusions:

• Integrated diagnostic approaches combining conventional and innovative methods are crucial.
• Interdisciplinary cancer centers provide optimized care for CUP patients.
• Refined therapeutic strategies are now available for patients with cancer of unknown primary.